The medication is commonly used for managing symptoms related to physical discomfort, inflammation, and fever. It is generally applied across domains where additional symptomatic support is needed, focusing on specific conditions in adults and adolescents (from 12 years of age).

This includes conditions presenting with acute episodes such as symptoms related to physical discomfort, the episodic manifestations of painful osteoarthritis, and the pain and cramping associated with primary dysmenorrhoea.

“The medicine is relevant for easing symptoms that create noticeable physiological strain and provides support that helps patients cope more steadily with difficult episodes.”

Quick Fact: Support for Symptom Manifestations

Quick Fact: Support for Symptom Manifestations The medicine is considered relevant when symptoms related to inflammatory or irritative states become more disruptive during flare-ups, and is helpful in situations where symptoms interfere with daily comfort.

Regulatory References

1. European Medicines Agency

Who is Eligible to Use Нимид?

Eligibility to use Нимид (Nimesulide) is strictly defined by regulatory authorities and is dependent on age, physiological status, and the absence of specific health conditions. The medicine is primarily intended for adults and adolescents from 12 years of age.

Official Contraindications and Restrictions

Regulatory documentation outlines several absolute contraindications, meaning the medicine must not be used in these populations or clinical states:

• Age: Children younger than 12 years old.
• Organ Function: Patients with any degree of hepatic impairment (liver dysfunction) or a history of hepatotoxic reactions to Nimesulide. It is also contraindicated in patients with severe renal impairment or severe heart failure.
• Gastrointestinal and Bleeding Risk: Individuals with an active gastrointestinal ulcer, bleeding, or perforation, or a history of recurrent ulceration or bleeding.
• Hypersensitivity: Patients with known hypersensitivity to Nimesulide, Aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• Reproductive Status: Women in the third trimester of pregnancy and women who are breastfeeding.

Use is not recommended for women who are attempting to conceive or who are in the first or second trimester of pregnancy. Elderly patients may use the medicine but require close clinical monitoring.

Nimesulide's official interaction profile, documented by regulatory authorities, focuses on both pharmacokinetic and pharmacodynamic constraints that align with its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Prohibited Combinations

Co-administration is formally contraindicated by regulatory labels for substances documented to increase severe toxicity risk. This includes alcohol and other known hepatotoxic medicines due to the potential for severe liver injury. Co-administration with other NSAIDs or Aspirin (at anti-inflammatory or analgesic doses) is also prohibited due to the increased risk of gastrointestinal ulceration and bleeding.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Agent/Class	Official Regulatory Outcome
Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, Corticosteroids	Increased pharmacodynamic risk of haemorrhage and gastrointestinal ulceration.
Lithium	Reduced renal clearance, leading to an increase in Lithium plasma levels and potential toxicity.
Methotrexate (at high doses)	Reduced renal clearance, leading to increased Methotrexate plasma levels.
CYP2C9 Inhibitors (e.g., Fluconazole)	Increased Nimesulide systemic exposure (AUC and Cmax).
Diuretics, ACE Inhibitors, ARBs, Ciclosporin	Increased risk of nephrotoxicity.

Population-Specific Notes

Elderly patients and those with impaired renal or hepatic function have a documented heightened susceptibility to the interaction risks associated with co-administered agents like anticoagulants and nephrotoxic medicines.

Drug-Food Interaction

The regulatory data indicates that taking Nimesulide with food does not significantly alter the total amount of drug absorbed ( AUC), but it may decrease the rate at which the drug reaches maximum concentration ( C max).

The mechanism of Nimesulide (Нимид) involves a targeted, multi-layered approach to modulate the biological processes initiated by inflammatory stimuli, focusing exclusively on the molecular and cellular level.

Preferential Action on Prostaglandin Synthesis

The core mechanism involves the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme. By blocking this enzyme, the drug suppresses the excessive, localized production of PGE2, a primary mediator of inflammation and fever. This targeted action reduces the signaling that promotes nociceptor sensitization and simultaneously modulates the thermal set point in the hypothalamus.

Modulation of Cellular Destruction Mechanisms

Beyond the core enzyme inhibition, Nimesulide engages in unique mechanisms that affect the activity of enzymes involved in tissue breakdown. The molecule acts as a scavenger of harmful reactive oxygen species and inhibits key enzymes like Myeloperoxidase (MPO) in immune cells. Furthermore, it modulates the activity of Matrix Metalloproteinases (MMPs), which are involved in tissue breakdown. This secondary domain affects the cellular cascades involved in propagating inflammatory signals and proteolytic activity.

The administration of Nimesulide focuses on the use of the minimal effective dose for the shortest possible duration. The medicine is administered through the oral route (as 100 mg tablets or granules for suspension) for systemic use, and via topical application (as a gel) for local effects.

---

The standard systemic dosage regimen for adults requires a 100 mg dose to be taken twice daily (bid). This establishes the maximum allowable daily dose at 200 mg. A crucial condition for oral administration is that the formulation must be taken after a meal. The entire course of systemic treatment is subject to an absolute time restriction: use must not exceed 15 days.

---

Usage patterns are specified for distinct populations. Adolescents aged 12 to 18 years should adhere to the standard 100 mg twice-daily regimen. However, systemic administration is contraindicated in children under 12 years of age. For older adults and patients with mild to moderate renal impairment, no routine dosage adjustment is required. If an oral dose is missed, patients are instructed to resume the schedule with the next dose at the usual time, without taking a double dose. This set of instructions describes the standardized approach to the drug's use.

Research Evidence / Overview of Studies for Нимид (Nimesulide)

---

Evidence for Short-Term Acute Pain Management

Research for Nimesulide's systemic use has primarily focused on the evaluation of the medicine for short-term, acute painful episodes. This body of evidence includes a large number of short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. The research examined outcomes related to physical discomfort, such as the measurement of changes in pain intensity scores and the evaluation of the speed of initial symptom change.

Studies compared the measurement of pain intensity scores between the studied group and the placebo group. Regulatory systematic reviews have documented consistent patterns of findings across this large volume of short-term research.

A significant gap lies in long-term effects, as follow-up durations were limited, reflecting the regulatory requirement that systemic Nimesulide evaluation should not exceed 15 consecutive days. Data for patients with significant pre-existing conditions (comorbidities) remain insufficient.

---

Evidence for Primary Dysmenorrhoea

Nimesulide was evaluated in research for the management of symptoms associated with primary dysmenorrhoea, a condition characterized by fluctuating or episodic manifestations. The research applied in studies examining patient-reported experiences consisted of short-term, episodic Randomized Controlled Trials (RCTs). These studies explored symptom patterns during specific menstrual cycles, focusing on patient-reported outcomes describing perceived discomfort, such as the measurement of cramping severity and the documentation of the concurrent use of other types of pain medication.

The studies monitored how symptoms evolved in the observed populations, reporting patterns of observed change in pain scores during the cycles where the medicine was used. Evidence derived from settings with varying symptom burdens also monitored the concurrent use of other types of pain medication. The research provides insight into short-term changes and was used by major regulatory authorities to classify the medicine for this specific, restricted indication.

---

What Is Still Uncertain About the Research

The available evidence highlights what is known—and what is still uncertain—about Nimesulide. A significant gap lies in long-term effects, as the short-term focus of the evidence means that data are still emerging regarding the outcomes of extended or repeated use. Research has explored the evaluation of the medicine for outcomes related to physical discomfort. However, comparative evidence is lacking for certain specific subgroups of the population. The research does not determine whether an individual will respond similarly, and study results reflect the specific conditions under which they were conducted. Ultimately, the limited information for long-term outcomes and the regulatory restrictions based on an evidence review define the largest current gap in the research landscape.

Key Studies & References Nimesulide: an update on its pharmacodynamics and pharmacokinetics and therapeutic efficacy in the management of pain and inflammation

Common questions about Нимид (FAQ)

---

Q: What is the difference between Nimesulide (Нимид) and other pain relievers?

Official product information indicates that Nimesulide is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification identifies its mechanism of action as a preferential cyclooxygenase-2 (COX-2) inhibitor.

Q: Why is Nimesulide restricted or forbidden in some countries?

Some regulatory authorities have suspended or restricted the use of Nimesulide due to a documented increased risk of serious liver toxicity (hepatotoxicity). This safety concern has led to its withdrawal or severe restriction in several countries, meaning its use is often limited to second-line treatment and short-term courses.

Q: Does Nimesulide affect blood clotting?

Yes, official warnings state that Nimesulide can interfere with the way blood cells called platelets function, which are essential for clotting. Due to this, regulatory documents carry a warning regarding the need for caution in patients who have a bleeding tendency or are taking other medicines that affect clotting.

Q: Is it true that Nimesulide is tolerated worse by older adults?

Studies show that elderly patients have an increased frequency of adverse reactions to Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in general, particularly serious gastrointestinal issues like bleeding. Regulatory documents require appropriate clinical monitoring for older adults using this medication due to these risks.

Q: What should I do if I experience nausea while taking Nimesulide?

Nausea is documented as a common side effect of this medicine. However, official safety warnings indicate that patients should discontinue treatment and seek medical assistance if they develop persistent nausea and vomiting, as these may be symptoms suggestive of severe liver injury.

Q: Can I take Nimesulide for a toothache?

The medicine is officially indicated for the treatment of acute pain. Toothache is a form of acute pain.

Q: How quickly does Nimesulide start to work?

Official studies on the medication's effects indicate a relatively rapid onset of pain relief, with noticeable effects often beginning within 15 minutes of taking the dose. The maximum concentration of the drug in the blood is typically reached within 1.2 to 2.8 hours.

Q: Is Nimesulide addictive or habit-forming?

Regulatory and safety documents confirm that Nimesulide is not known to be habit-forming or addictive.

Q: Is a prescription required to buy Nimesulide?

Yes, in most jurisdictions, Nimesulide is classified as a prescription-only medicine. This means it requires authorization and a doctor's prescription for purchase.

Q: Are Nimid and Nimesil the same medicine?

The medicine contains the single active ingredient, Nimesulide. Different products, such as Нимид and Nimesil, are simply various brand names under which this single active ingredient is marketed globally. All share the same primary component.

Q: Can Nimesulide cause drowsiness?

Yes, official product information lists both dizziness and drowsiness (sleepiness) as possible side effects.

Q: How does Nimesulide affect blood pressure?

Regulatory documents indicate that Nimesulide may interact with certain medicines used to treat high blood pressure, such as diuretics. Additionally, uncontrolled high blood pressure (hypertension) is listed as a health condition that requires caution when using this medicine.

Q: Can I take Nimesulide if I have gastritis?

Nimesulide is an NSAID, and its regulatory labeling carries a warning that caution is required in patients with gastrointestinal disorders. Official warnings list conditions like severe gastritis, active stomach ulcers, and gastrointestinal bleeding as reasons why the medication should be avoided.

Q: Does Nimesulide help with tension headaches?

The medicine is officially indicated for the treatment of acute pain. Headaches are a common form of acute pain.

Q: How long does the effect of Nimesulide last after taking a dose?

The medicine is typically administered twice daily. Studies show the mean terminal elimination half-life, which is the time it takes for half the drug to leave the body, is relatively short (1.8 to 4.7 hours).

Q: Do I need to stop taking Nimesulide before surgery?

Official warnings state that Nimesulide interferes with the function of platelets, which are essential for blood clotting. Due to this effect and the potential for increased bleeding risk, medical conditions requiring surgery are often listed as a caution or contraindication in regulatory documents.

Q: Are there interactions between Nimesulide and herbal supplements?

Official interaction lists typically focus on pharmaceutical products. Regulatory text indicates that co-administration with herbal remedies or supplements requires discussion with a healthcare provider due to the potential for unknown risks of interaction.

Q: What precautions are described for people with diabetes when taking Nimesulide?

Regulatory documents indicate that Nimesulide may interact with antidiabetic medicines, such as insulin. Due to the potential interaction, official product information requires that patients taking antidiabetic medicines undergo close clinical monitoring.

Q: Does Nimesulide interact with contraceptives?

There are documented reports suggesting a potential interaction between Nimesulide and oral contraceptives. This is based on concerns that the combined use of these medicines could increase the risk of liver damage due to similar effects on the liver.

Q: Are there driving restrictions when taking Nimesulide?

Yes, Nimesulide can cause dizziness and drowsiness as side effects. Regulatory documents contain a warning that patients must use caution and refrain from driving or operating heavy machinery if they experience these effects.

How to Store and Dispose of Nimesulide

Storage Conditions

Nimesulide must be stored at a temperature not exceeding 25 C (77 F) to maintain its stability. The product should be kept in the original container to ensure protection from moisture. This is essential to preserve the labeled shelf-life. A mandatory requirement is to store the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Nimesulide must be disposed of according to local requirements for pharmaceutical waste. It is officially stated that the medicine must not be thrown into household wastewater or general refuse. Following pharmaceutical waste regulations prevents environmental contamination.